For research and educational purposes only. Not medical advice.

Melanotan II Reference

Educational, not medical advice reference for Melanotan II: Skin/Hair; regulatory status, evidence posture, source review, and schedule notes. A…

Reference summary

Melanotan II pharmacology is broadly characterized in preclinical work, but there is no modern human clinical program supporting tanning / sexual-health / body-composition community claims. Adverse-event reports including priapism and unpredictable pigmentation are documented.

Regulatory and posture

Categories
Skin/Hair
Aliases
MT-II, α-MSH analog
Evidence posture
preclinical - FDA has issued consumer safety communications about melanotan products. Priapism, nausea, unpredictable pigmentation changes, and concerns about melanocytic lesions are commonly reported in adverse-event literature.
Regulatory status
No FDA-approved Melanotan II drug label. FDA has issued consumer safety communications about melanotan tanning products, citing unapproved marketing, unknown purity, and documented adverse events. Melanotan II is not the same compound as FDA-approved afamelanotide (Scenesse / Melanotan I).
Content review status
research reference

Selected public sources

Related tools